Industry News

InVivo Therapeutics Holdings Corp. today announced that Northwestern Medicine in Chicago, IL has been added as a clinical site for The INSPIRE Study: In Vivo Study of Probable Benefit of the Neuro- Spi nal Scaffold™ for Safety and Neurologic Re covery in Subjects with Complete Thoracic AIS A Spinal Cord Injury. Surgeries will be performed at the Northwestern Memorial Hospital, an 894- bed Level I trauma center. “Chicago, as with other major metropolitan areas,..."/>
InVivo Therapeutics Announces Northwestern Medicine as New Site for INSPIRE Study
Aimmune Therapeutics, Inc., a biopharmaceutical company developing CODIT™ treatments for life-threatening food allergies, today announced that management will host a conference call to highlight the results of an independent academic..."/>
Aimmune Therapeutics to Host Conference Call on Potential Positive Implications for AR101 Development From Independent Academic Study Showing Oral Immunotherapy Induces Sustained Unresponsiveness in Young Peanut-Allergic Children
Centene Corporation announced today it will present at the Wells Fargo 2016 Healthcare Conference, to be held September 7-8, 2016, at Westin Waterfront in Boston. Centene is scheduled to present on Wednesday, September 7, 2016 at 11:05 AM. A simultaneous live audio webcast is also available at: https://cc.talkpoint.com/well001/090716a_ae/?"/>
Centene Corporation To Present At Wells Fargo 2016 Healthcare Conference
Valeant Pharmaceuticals International, Inc. today announced that it has obtained the requisite lender approval for an amendment to its credit facility. The Company expects to close the amendment next week, subject to customary closing conditions. reduce the interest coverage maintenance covenant to 2.0 x, providing additional headroom provide additional flexibility to sell assets permit the issuance of secured notes with shorter..."/>
Valeant Pharmaceuticals Receives Lender Consent For Credit Facility Amendment
Pediapharm Inc. is pleased to file its first quarter financial results ended June 30, 2016. All dollar amounts are expressed in Canadian currency unless otherwise indicated and results are reported in accordance with IFRS accounting principles."/>
Pediapharm Announces First Quarter Financial Results-Increase of 47% in Revenue and Operating Profit of $1.7 Million
BeiGene, Ltd., a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that it has received Clinical Trial Application approval from the China Food and Drug Administration to conduct clinical trials in China with BGB-290, a highly potent and selective PARP inhibitor. China is the third territory in which BGB-290 has received..."/>
BeiGene Receives Approval to Initiate Clinical Trials in China with PARP Inhibitor BGB-290
OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $10.00 per share. Net proceeds to OncoMed from this offering are expected to be approximately $51.4 million after underwriting discounts and commissions and estimated offering..."/>
OncoMed Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Spectral Medical Inc.,, a Phase III company developing the first treatment for patients with endotoxemic septic shock guided by a companion diagnostic, today announced that it expects to release primary end point results for its pivotal EUPHRATES trial immediately after the end of the third quarter ended September 30, 2016. The trial was completed in June of this year. In addition, the Company announced that the United States Food and Drug..."/>
Spectral on Track With Regulatory Pathway for Novel Septic Shock Treatment
Allergan plc a leading global pharmaceutical company, today announced that Brent Saunders, Allergan's CEO and President, will present at the 2016 Wells Fargo Healthcare Conference on Thursday, September 8, 2016 at 10:30 a.m. ET at the Westin Waterfront Hotel in Boston, MA. The presentation will be webcast live and can be accessed on Allergan's Investor Relations web site at http://ir.allergan.com. The webcast can also be accessed through the..."/>
Allergan to Present at 2016 Wells Fargo Healthcare Conference
EnteroMedics revealed on Wednesday the addition of Gary Blackford to its board of directors, effective immediately. In conjunction with the new appointment, Anthony Jansz will step down from the company's board with immediate effect. Blackford is currently a member of the board of directors for Wright Medical Group NV, Halyard Health Inc and PipelineRx."/>
EnteroMedics elects Gary Blackford to board
Mallinckrodt plc, a leading global specialty pharmaceutical company, announced today it will build out a new campus for its fast-growing Specialty Brands organizations in the Somerset Financial Center, 1405-1425 Route 206, in Bedminster. Mallinckrodt will invest greater than $80 million in New Jersey, and anticipates approximately 400 employees will occupy the new space in the first quarter of 2017.."/>
Mallinckrodt Locates Growing Specialty Brands Businesses In Bedminster, N.J.; Continues Significant St. Louis Reinvestment
Endologix Inc reported on Wednesday that it has treated the first two patients with abdominal aortic aneurysms in New Zealand with its Ovation Alto Abdominal Stent Graft System. The company added that both the patients were treated by Andrew Holden, MD and Andrew Hill, MD of Auckland City Hospital, Auckland, New Zealand. Ovation Alto is the newest device in the Ovation platform of abdominal stent graft systems, which has excellent clinical..."/>
Endologix treats first two AAA patients with Ovation Alto Abdominal Stent Graft System
Quidel Corporation disclosed on Wednesday the receipt of approval from the US Food and Drug Administration to market its Solana Trichomonas assay to aid in the diagnosis of trichomoniasis, a sexually transmitted disease. This Solana Trichomonas assay is used for the detection of nucleic acids isolated from clinician-collected vaginal swabs and female urine specimens obtained from symptomatic or asymptomatic females to aid in the diagnosis..."/>
Quidel awarded US FDA clearance for Solana Trichomonas assay for diagnosis of trichomoniasis
Illumina Inc., XOMA Corp., Lexicon Pharmaceuticals Inc., and VIVUS Inc.. According to Morgan Stanley's Adam Parker, U.S."/>
Biotech Stocks on Investors' Radar -- Illumina, XOMA, Lexicon Pharma, and VIVUS
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, today announced positive results from its Phase 2 clinical trial, of A-101 Topical solution for the treatment of common warts. A-101 is a proprietary formulation of high-concentration hydrogen peroxide currently under development as a prescription treatment for common warts.. WART-201 was a randomized, double-blind, vehicle-controlled, clinical trial designed to..."/>
Aclaris Therapeutics Announces Positive Results in Phase 2 Clinical Trial of A-101 for Treatment of Common Warts  
Derma Sciences, Inc., a tissue regeneration company focused on advanced wound and burn care, announces the appointment of Russell Olsen as President of Advanced Wound Care. Olsen is President and Chief Executive Officer of BioD, LLC, a regenerative medicine products company Derma Sciences acquired earlier this month. “I am delighted Russ Olsen is expanding his role on our executive team from head of our BioD subsidiary to President of Advanced Wound Care, our..."/>
Derma Sciences Names Russell Olsen President of Advanced Wound Care
Nymox Pharmaceutical reported on Wednesday the completion of private placements and other investments for a total of USD2.24m. Under the terms of the private placement, the company sold 965,649 shares at an average price of USD2.32, with no warrants. The company added that it will use the funds for general corporate purposes."/>
Nymox raises USD2.24m from private placements
Teva Pharmaceutical Industries reported on Thursday the receipt of the European Commission's marketing authorisation for CINQAERO in the 28 countries of the European Union in addition to Norway, Liechtenstein and Iceland. The company said CINQAERO is a humanized interleukin-5 antagonist monoclonal antibody for add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled..."/>
Teva Pharmaceutical Industries passes EC marketing authorisation for CINQAERO in 28 EU countries
Auris Medical Holding AG, a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today..."/>
Auris Medical Provides Business Update and Reports Second Quarter 2016 Financial Results
Perrigo Company disclosed on Wednesday that it has entered into an agreement to acquire Peachtree City, Georgia-based, Geiss, Destin& Dunn Inc for an undisclosed fee. Geiss, Destin& Dunn is a small national distributor of over-the-counter healthcare and consumer goods products to the non-chain retail and institutional markets. The transaction is expected to close by the end of August."/>
Perrigo to buy Geiss, Destin & Dunn for undisclosed amount
Veeva’ s industry cloud solutions gain momentum as companies unify business processes for faster time to market and greater compliance. PLEASANTON, Calif.---- As life sciences companies continue their transition from legacy on-premises and horizontal cloud software to industry-specific cloud applications, Veeva Systems is strengthening its position as a fast-growing, strategic vendor in the industry across its most critical functions. According to Gartner, Veeva’ s..."/>
Top Industry Analysts Rank Veeva Systems Among Largest, Most Strategic Software Vendors in Life Sciences
NT Pharma Announces 2016 Interim Results
Inotek Pharmaceuticals Corporation, a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced that Patrick Machado, JD, has been appointed to its Board of Directors. Machado will serve on the Audit Committee. Machado most recently served as Co-Founder, Chief Business Officer and Chief Financial Officer of Medivation, Inc., a biopharmaceutical company, for 11..."/>
Inotek Pharmaceuticals Appoints Patrick Machado, JD, to Board of Directors

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Consumer Discretionary590 Articles
Information Technology569 Articles
Financials440 Articles
Industrials354 Articles
Health Care328 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.